Replies to post #182321 on Biotech Values

[DewDiligence]

[if NVS]…changed their mind about the HCV space in such a short time (2012 to now) because they feel the patient pool would be somewhat exhausted by the time they came to market.

NVS’ decision to exit from HCV probably had more to do with the limitations of DEB025, NVS’ cyclophilin inhibitor that had previously been on FDA clinical hold and recently underwent a DDI study with EDP239 in healthy volunteers.